ALK and non-small cell lung carcinoma: Wekken A. et al. 30 evaluated tumour response rate and survival after crizotinib treatment of 29 consecutive patients with ALK-positive advanced NSCLC diagnosed by FISH and/or Ventana ALK D5F3 IHC on small biopsies or fine needle aspirations (FNA).